Crestor
(rosuvastatin)ApprovedSmall molecule
AstraZenecaRosuvastatin is used to lower cholesterol and triglycerides in the blood, which helps reduce the risk of heart disease and stroke.[2] Crestor is currently approved and in use across 80 indications[4].[1]
Crestor is one of 1204 small molecule programs targeting Acute Coronary Syndrome. It is currently in Approved.
80
Indications
531
Total Trials
9
Active Trials
1,203
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 79 indications
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Zoladex
TTerSera Therapeutics LLC
Phase 3
Crestor
AstraZenecaApproved
Talzenna
PfizerPhase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Tecentriq
RochePhase 3
Glucophage
EMD SeronoPhase 3
Truqap
AstraZenecaPhase 3
Ritalin
NovartisPhase 3
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Statin38 trials
Show 35 more trials
Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
Unknown status·—·Phase 4·NCT00972829·30 enrolled
Rosuvastatin Affecting Aortic Valve Endothelium
Completed·—··NCT00114491·200 enrolled
Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve
Completed·—·Phase 4·NCT01490398·56 enrolled
Intensive Statin Therapy in Patients With AMI
Unknown status·—·Phase 2·NCT01923077·140 enrolled
Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels
Completed·—·N/A·NCT06910098·195 enrolled
Interaction23 trials
Show 20 more trials
Atorvastatin7 trials
Show 4 more trials
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06601517·30 enrolled
Metformin6 trials
92 more indications
Treatment4 trials
Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?
Unknown status·—·Phase 4·NCT00295373·48 enrolled
Efficacy and Safety4 trials
Show 1 more trial
Hypercholesterolaemia3 trials
Efficacy3 trials
"Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects"
Completed·—·Phase 4·NCT03677297·10 enrolled
Ischemic stroke3 trials
Cardiovascular3 trials
Metabolic Syndrome3 trials
Adult Subject2 trials
Atherosclerotic Plaque2 trials
Clinical Trial2 trials
Acute Coronary Syndrome2 trials
Breast Cancer2 trials
Nephropathy2 trials
Dyslipidemia2 trials
Heart Failure2 trials
Type 2 Diabetic Patients2 trials
Tics2 trials
Coronary Artery Disease2 trials
Semaglutide1 trial
Sclerosing Cholangitis1 trial
Familial Hypercholesterolemia1 trial
Dialysis Patients1 trial
Fidaxomicin1 trial
Diabetic Polyneuropathy1 trial
Prostate Cancer1 trial
Venous Thromboembolism1 trial
Cirrhosis1 trial
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT05832229·256 enrolled
Valve Surgery1 trial
Endometrial Carcinoma1 trial
Renal Impairment1 trial
Solid Tumor1 trial
Homozygous Familial Hypercholesterolemia1 trial
AIN1 trial
Dual Antiplatelet Therapy1 trial
Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
Completed·—·Phase 2·NCT04824911·376 enrolled
Paroxysmal atrial fibrillation1 trial
Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation
Unknown status·TThe Third Xiangya Hospital of Central South University·Phase 4·NCT02502110·346 enrolled
Midazolam1 trial
Adult1 trial
Chronic Obstructive Pulmonary Disease1 trial
Mixed Dyslipidemia1 trial
Cardiovascular Events1 trial
Non-Small Cell Lung Cancer1 trial
Single Dose1 trial
Hyperlipidemia1 trial
Systemic Inflammation1 trial
Joint Disease1 trial
Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease
Completed·—·N/A·NCT01389388·114 enrolled
Mortality1 trial
Hemodynamic1 trial
Malignant Tumors1 trial
Coronary Atherosclerosis1 trial
Chronic Kidney Disease1 trial
Effect of Drug1 trial
Cardiovascular Disease1 trial
Necrosis1 trial
Chest pain1 trial
Acute Kidney Injury1 trial
Ischemia1 trial
Methotrexate1 trial
Atherosclerosis1 trial
Venous thrombosis1 trial
Proteinuria1 trial
Platelet Reactivity1 trial
Heart Disease1 trial
Concentration1 trial
Preeclampsia1 trial
Effect of Rosuvastatin on the Clinical Features of Preeclampsia
Unknown status·—·Phase 2·NCT04303806·80 enrolled
Major Adverse Cardiac Events1 trial
Cardiomyopathy1 trial
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
Not yet recruiting·—·Phase 1·NCT06304896·150 enrolled
Advanced Solid Tumors1 trial
Ulcerative Colitis1 trial
Systemic Lupus Erythematosus1 trial
Percutaneous Coronary Intervention1 trial
Regulatory
FDA Approval Timeline[5]
Aug 12, 2003
CRESTOR
NDA NDA021366
Dec 18, 2018
EZALLOR SPRINKLE
NDA NDA208647
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Crestor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for rosuvastatin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- HMG-Coa Reductase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Feb 12, 2036
Earliest patent expiration — generic entry possible after this date
Patent #Expires
10413543Feb 12, 2036